Dat	e:Jul .7 th ,2021					
Your Name:Tianqi Wu						
Manuscript Title:Comprehensive analysis of alternative splicing profiling reveals novel events associated with						
pro	prognosis and the infiltration of immune cells in prostate cancer					
Ma	nuscript number (if known):	:TAU-21-585				
rela par trar	ted to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content o essarily indicate a bias. If	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.)		
	following questions apply t	to the author's relationship	os/activities/interests as they relate to the current			
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.			
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items	5,		
			0 17 11 10			
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	,			
		needed)				
		Time frame: Since the initia	planning of the work			
1	All support for the present	X None				
1	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	ivo time minit for tims item.					

	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated	XNone				
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				
-	December to a bourgassis for	V. Nore				
5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus,					
	manuscript writing or educational events					
6	Payment for expert	X None				
0	testimony					
7	Support for attending	XNone				
	meetings and/or travel					
8	Patents planned, issued or pending	XNone				
9	Participation on a Data	XNone				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role in other board, society,	XNone				
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	XNone				
12	Receipt of equipment,	X_None				
	materials, drugs, medical					

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Dat	te:Jul .7 th ,2021						
Υοι	ır Name:Wenfeng Wang						
Manuscript Title:Comprehensive analysis of alternative splicing profiling reveals novel events associated with							
prognosis and the infiltration of immune cells in prostate cancer							
Ma	Manuscript number (if known):TAU-21-585						
rela pai tra	ated to the content of your r ties whose interests may be	manuscript. "Related" me affected by the content of essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.				
	e following questions apply t nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current				
to	· · · · · · · · · · · · · · · · · · ·	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.				
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items				
		Name all entities with	Specifications/Comments				
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)				
		none (add rows as	institution)				
		needed)					
		Time frame: Since the initia	al planning of the work				
	All support for the present	X None					
	manuscript (e.g., funding,						
	provision of study materials,						
	medical writing, article						
	processing charges, etc.) No time limit for this item.						
	ino time ilmit for this item.						
			 				

	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated	XNone				
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				
-	December to a bourgassis for	V. Nore				
5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus,					
	manuscript writing or educational events					
6	Payment for expert	X None				
0	testimony					
7	Support for attending	XNone				
	meetings and/or travel					
8	Patents planned, issued or pending	XNone				
9	Participation on a Data	XNone				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role in other board, society,	XNone				
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	XNone				
12	Receipt of equipment,	X_None				
	materials, drugs, medical					

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Date	e:Jul .7 th ,2021			
You	r Name: Yanhao Wang			
Mar	nuscript Title:Comprehe	nsive analysis of alternati	ive splicing profiling reveals novel events associated wi	ith
pro	gnosis and the infiltration	of immune cells in prosta	te cancer	
Mar	nuscript number (if known)	:TAU-21-585		
rela part tran	ted to the content of your r ties whose interests may be	manuscript. "Related" mea e affected by the content o essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment you are in doubt about whether to list a so.	to
	following questions apply t	to the author's relationshi	ps/activities/interests as they relate to the current	
to tl		ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other ite	ms,
		Name all entities with	Specifications/Comments	
		ivallie all cilules with	Specifications/ comments	
		whom you have this	(e.g., if payments were made to you or to your	
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)	
		relationship or indicate none (add rows as		
		relationship or indicate none (add rows as needed)	institution)	
		relationship or indicate none (add rows as	institution)	
		relationship or indicate none (add rows as needed)	institution)	
1	All support for the present	relationship or indicate none (add rows as needed)	institution)	
1	manuscript (e.g., funding,	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	
1	manuscript (e.g., funding, provision of study materials,	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed) Time frame: Since the initia	institution)	

	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated	XNone				
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				
-	December to a bourgassis for	V. Nore				
5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus,					
	manuscript writing or educational events					
6	Payment for expert	X None				
0	testimony					
7	Support for attending	XNone				
	meetings and/or travel					
8	Patents planned, issued or pending	XNone				
9	Participation on a Data	XNone				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role in other board, society,	XNone				
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	XNone				
12	Receipt of equipment,	X_None				
	materials, drugs, medical					

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Dat	e:Jul .7 th ,2021		
You	r Name: Mengfei Yao		
Ma	nuscript Title:Comprehe	nsive analysis of alternati	ive splicing profiling reveals novel events associated with
pro	gnosis and the infiltration	of immune cells in prosta	te cancer
Mai	nuscript number (if known):	:TAU-21-585	
rela par trar	ted to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content o essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.
	following questions apply t nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all and the annual late	Constitution (Comments
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	X None	
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	ino time minition tins item.		

	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated	XNone			
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
-	December to a bourgassis for	V. Nore			
5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or educational events				
6		X None			
0	Payment for expert testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Date:Jul .7 th,2	2021	
Your Name: Leile	ei Du	
		ternative splicing profiling reveals novel events associated wit
prognosis and the i	infiltration of immune cells in j	prostate cancer
Manuscript number	r (if known):TAU-21-585	<u> </u>
related to the conte parties whose inter- transparency and do	ent of your manuscript. "Related ests may be affected by the con	ose all relationships/activities/interests listed below that are d" means any relation with for-profit or not-for-profit third ntent of the manuscript. Disclosure represents a commitment toias. If you are in doubt about whether to list a you do so.
The following quest manuscript only.	ions apply to the author's relat	tionships/activities/interests as they relate to the current
to the epidemiology medication, even if In item #1 below, re	y of hypertension, you should d that medication is not mention	eported in this manuscript without time limit. For all other item
	Name all entities wi whom you have this relationship or indic none (add rows as	(e.g., if payments were made to you or to your
	needed)	- initial planning of the couple
	Time frame: Since th	ne initial planning of the work
All support for th	ne present X None	
manuscript (e.g.,		
provision of stud		
medical writing,		
processing charg No time limit for		

	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated	XNone			
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			
5	Payment or honoraria for	X None			
3	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone			
10	Leadership or fiduciary role	XNone			
10	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Da	te:Jul .7 th ,2021		
Υοι	ır Name: Xiingming Zhan	g	
Ma	nuscript Title:Comprehe	nsive analysis of alternat	tive splicing profiling reveals novel events associated with
pre	ognosis and the infiltration	of immune cells in prosta	te cancer
Ma	nuscript number (if known)	:TAU-21-585	
rela pai tra	ated to the content of your r rties whose interests may be	nanuscript. "Related" me affected by the content of essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a poso.
	e following questions apply t nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current
to		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
l	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
materials, drugs, medical			

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Dat	te:Jul .7 th ,2021		
Υοι	ır Name: Yongqiang Hua	ng	
Ma	nuscript Title:Comprehe	nsive analysis of alternat	ive splicing profiling reveals novel events associated with
pro	ognosis and the infiltration	of immune cells in prosta	te cancer
Ma	nuscript number (if known)	:TAU-21-585	
rela pai tra	ated to the content of your r ties whose interests may be	nanuscript. "Related" me affected by the content of essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.
	e following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	ino time ilmit for this item.		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
materials, drugs, medical			

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Dat	te:Jul .7 th ,2021		
	ır Name: Jianhua Wang		
			ive splicing profiling reveals novel events associated with
	ognosis and the infiltration		te cancer
Ma	nuscript number (if known):	:TAU-21-585	
rela pai tra	ated to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content o essarily indicate a bias. If	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.
	e following questions apply t nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current
to	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items
		Name all autition with	Considerations (Community
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	I planning of the work
1	All support for the present	X None	
-	manuscript (e.g., funding,	XNONC	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	time mint for time item.		
	1	1	<u> </u>

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role	XNone	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

You Ma pro	e:Jul .7 th ,2021 r Name: Hongbo Yu nuscript Title:Comprehe gnosis and the infiltration o nuscript number (if known):	of immune cells in prostat		h
rela par trar	ited to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o essarily indicate a bias. If	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.	D
	following questions apply t nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.	
	tem #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other item	s,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	l planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role	XNone	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			

Dat	e:Jul .7 th ,2021					
	r Name: Xiaojie Bian					
Manuscript Title:Comprehensive analysis of alternative splicing profiling reveals novel events associated with						
pro	prognosis and the infiltration of immune cells in prostate cancer					
Mai	nuscript number (if known):	:TAU-21-585				
rela par trar	ted to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content of essarily indicate a bias. If	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment to you are in doubt about whether to list a so.	ס		
	following questions apply t	o the author's relationship	os/activities/interests as they relate to the current			
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.			
	em #1 below, report all sup time frame for disclosure is	•	l in this manuscript without time limit. For all other item	s,		
		A. H. 1711 711	0 17 11 10			
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	,			
		needed)				
		Time frame: Since the initia	l planning of the work			
1	All support for the present	X None				
1	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	ino time minit for this item.					

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role	XNone	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		

	writing, gifts or other services		
13	Other financial or nonfinancial interests	XNone	

None.			